Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Oral etoposide combined with oral arsenic plus retinoic acid for two cases with newly diagnosed high-risk acute promyelocytic leukemia during COVID19 pandemic

Sheng-ye Lu a, Wen-jing Li a, Rui Lou a, Rui Ma a, Ji-hong Zhu b, Hao Jiang Prof., MD. a,∗

a Peking University Institute of Hematology, Peking University People’s Hospital, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China
b Department of Emergency, Peking University People’s Hospital, Beijing, China

ARTICLE INFO

Key words:
Acute promyelocytic leukemia
High-risk
Early deaths
Cytoreductive therapy

ABSTRACT

Acute promyelocytic leukemia (APL) is a highly curable hematologic malignancy. The major factor influence prognosis of APL is early deaths (ED) during the course of induction therapy, especially in high-risk APL. Therefore, effective reduction of white blood cells and correction of coagulation abnormalities are the key points of treatment for high-risk APL. Due to COVID19 pandemic in China since Jan 2020, some patients with hematologic malignancies suspected of COVID-19 infection had been isolated and traditional intravenous chemotherapy drugs is not available in isolated wards. We had explored a regimen of oral etoposide to reduce the tumor burden for high-risk APL and dual induction with retinoic acid (ATRA) and oral arsenic realgar-indigo naturalis formula (RIF), and finally two cases of high-risk APL patients received complete remission in one month. It is indicated that pure oral induction regimen: oral etoposide, ATRA and RIF provides a novel therapy in outpatient clinics.

Acute promyelocytic leukemia (APL) is a highly curable hematologic malignancy. The clinical characteristics are unique: 1. The onset of the disease is often accompanied by severe bleeding tendency and patients are prone to disseminated intravascular coagulation (DIC); 2. The typical feature of the APL cell and classic cytogenetics is t (15;17) (q22; q12) or typical molecular change are diagnostic criteria [1]. Retinoic acid (ATRA) and arsenic highly altered the prognosis of APL with the complete remission rate 90–94% or higher and diseases free survival (DFS) rate 80–90% or higher [2–4].

2019 ELN recommendations defined APL patients with a WBC count ≤10 × 10⁹/L before induction as low risk and APL patients with a WBC count>10 × 10⁹/L as high risk, which definitely emphasize the critical role of initial WBC count on the prognosis [5]. ATRA plus ATO-based regimen with addition of some cytoreductive chemotherapy were used in high-risk APL patients, guidelines from ELN and NCCN recommended chemotherapy (idarubicin or daunorubicin alone or combined with cytarabine),or Gemtuzumab ozogamicin (GO) as cytoreductive therapy [5, 6]. 2018 Chinese guideline for APL recommended hydroxyurea (Hu), anthracyclines and cytarabine as cytoreductive therapy [7].

Despite ATRA and ATO highly altered the prognosis of APL, early deaths remain the major effect on cure rate of APL. Park et al. reported ED rate of APL in induction is 10–17.5% in [8], and a retrospective study in Brazil reported 43 out of 134 (32%) patients died during induction and the bleeding complications were the most frequent cause of early deaths, 26/43 (60.5%) [9]. Several studies demonstrated that leukocytosis is prone to coagulopathy (hemorrhagic death), DS and severe acute respiratory syndrome (ARDS) [10, 11]. Therefore, effective and safe reduction of WBC count is the key point to reduce the early mortality of high-risk APL. Single agent Hu is difficult to control the rapid multiplication of APL cells in high-risk patient, and oral anthracyclines were not available in China, so we try to use oral etoposide instead.

In December 2019, novel coronavirus pneumonia cases were reported in Wuhan, Hubei Province, World Health Organization (WHO) defined it as coronavirus disease 2019 (COVID-19). It rapidly spread, resulting in a global pandemic. [12]. COVID-19 viral RNA detection by PCR is specific diagnostic marker, however, the sensitivity of nasopharyngeal swab-PCR in COVID-19 patients is only nearly 30%, so negative results of PCR can’t exclude COVID-19 infection. Strictly isolated suspected patients to certain area (febrile clinics or isolation wards in emergency rooms) prevented transmission in hospital [13]. Intravenous
chemotherapy was not available in isolation ward.

During COVID-19 pandemic, our center explored the regimen of oral etoposide as cytoreductive therapy combined with oral RIF plus ATRA based oral drug induction regimen for two high-risk APL patients, both of the patients reached complete remission in about one month.

1. Case 1

Patient No 02,048,211, male, 21 years old, 176 cm/67 kg, he went to the outpatient clinics due to intermittent fever for more than 2 months on Jan 30th 2020.

The patient had fever on Dec 1st, 2019, without chills or other symptoms, Tmax of 38.2 °C. He went to the local hospital and received some Chinese traditional medicine to relieve symptoms, from then on patient had intermittent low-grade fever. On January 30, 2020, patient suffered from gingival bleeding, he carried out some laboratory tests in the local hospital. CBC: WBC 28.63 × 10^9/L, Hb 94 g/L, PLT 7 × 10^9/L. Coagulation analysis: PT 15.5 s, Fib 120 mg/dL, d-dimer 2614 ng/ml. Chest CT showed infection in the upper and middle lobe of the right lung; localized atelectasis in the lingual segment of the left upper lobe and possible infection; and localized atelectasis in the lower lobe of the left lung (Fig. 1). The patient was controlled as a suspected case in the isolation ward according to fever, multiple pulmonary patchy shadows and a history of direct contact with relatives in Wuhan, although COVID-19 PCR of throat swab was negative three times.

On Feb 1st 2020, the patient had dry tap bone marrow aspiration, and peripheral blood (PB) smear showed typical APL. The patient was treated with ATRA, Hu, allopurinol and sodium bicarbonate for leukemia and with imipenem for anti-infection and with adequate supportive transfusion of red blood cells, platelets, fibrinogen and prothrombin complex. On Feb 2nd 2020, patient complained about headache and dizziness. No abnormality was found on brain CT scan. CBC: WBC 25.95 × 10^9/L, Hb 62 g/L, PLT 8 × 10^9/L, and leukostasis was suspected and oral Vp-16 100 mg Qd (Brand name: Lastet; Manufacturer: kabuskiki kaisha Japan Co., Ltd) was taken to reduce tumor burden and dexamethasone 5 mg QD preventing DS. On Feb 10th 2020 coagulopathy was corrected completely. On Feb 12th 2020 PML-RARA (Bcr1 isoform) in peripheral blood was 80.0%, so APL (high-risk) was diagnosed. RIF 60 mg/kg/d were administrated. During the course of induction, patient suffered from intermittent fever, pulmonary infection and acute orchi-epididymitis, so imipenem, vancomycin, oseltamivir and voriconazole were administrated for anti-infection. We monitored the complete blood count trend (Fig. 3-I). Hepatic function: ALT 21–72 U/L, AST 23–49 U/L, TBL 12.1–14.7umol/L. On February 25th, 2020, the chest CT examination showed that both lung lesions returned to normal. On Mar 3rd, 2020, CBC: WBC 2.28 × 10^9/L, Hb 75 g/L, PLT 88 × 10^9/L, and peripheral blood smear showed no APL cells. On Mar 3rd, 2020, bone marrow aspiration showed no promyelocytes, PML-RARA quantification in bone marrow 8%. Lumbar puncture and intrathecal injection were performed to prevent central nervous system leukemia, routine
biochemical test of cerebrospinal fluids showed no abnormality. The patient achieved hematological remission, and all other complications were cured. Case 1 patient was treated with VP16 750 mg and Hu 11 g in total, 35 days of ATRA (25 mg/m$^2$/d) and 28 days of RIF (60 mg/kg/d), then morphological evaluation of bone marrow showed complete remission. The patient only suffered from grade 1 hepatic dysfunction, no renal dysfunction and no QTc prolongation. The coagulopathy was corrected completely on the 8th day after ATRA. CBC returned to normal on 45 days since the initial treatment. 34 g fibrinogen, 10 U red blood cells and 17 U platelets were infused in total.
2. Case 2

Patient No 02,048,387, female, 50 years old, 154 cm/65 kg, she went to the fever clinics due to ecchymosis for 2 weeks and headache for 1 day.

Multiple ecchymosis was found in her lower extremities since middle March 2020, however she did not go to the hospital for further examination. Then, the activity tolerance decreased gradually. On Mar 27th, 2020, a sudden onset with high fever (Tmax 39.1 °C) was observed, accompanied by headache, no disturbance of physical activity, no abnormal sensation and no disturbance of consciousness. She went to fever clinics in our hospital. CBC showed WBC 14.09 × 10^9/L, Hb 92 g/L.
injection were performed on 2020–2020: divided into three times) were administrated. During the course of dual induction, patient suffered from intermittent fever, pulmonary infection, gingival abscess and Gram positive cocci sepsis (Staphylococcus aureus) owing to high fever and new cerebral hemorrhage. The patient was isolated in fever clinics for treatment.

2020–3–29 The patient was diagnosed as APL. The morphology showed 96% hypergranular APL cells, and MPO is strong positive. FCM: 84.14% abnormal clonal myeloid cells which express CD33,CD117,CD9, CD64,CD13,CD123, and CD7,CD34,CD10,CD19,CD56,CD2,CD15 are all negative. PML-RARA (Bcr1 isoform) is positive 67.4% and Chromosome Analysis is t (15;17) (q24;q21). ATRA 20mgQd-Bid and Hu 3 g/d was administered for leukemia. 2020–3–25 WBC elevated to 24.1 × 10^9/L, and patient complained about headache, so oral Vp-16 was given to reduce tumor burden, and dexamethasone 5 mg QD preventing DS.

Therefore, we chose ATRA plus RIF regimen as basic therapeutic drugs for acute promyelocytic leukemia (APL) patients. 2018 Chinese guideline recommended Hu as the cytoreductive agent for ATRA plus intravenous ATO in non-high-risk APL patients [14].

In particular, early deaths (ED) mostly due to the disease-associated coagulopathy, and hemorrhagic events account for 40–65% of ED, and the most common is cerebral hemorrhage and cerebral hemorrhage is the most common cause [10,15]. High-risk APL patients are prone to hemorrhagic death, DS and leukostasis. Therefore, cytoreductive therapy can help reduce the incidence fatal complications of high-risk APL.

Etoposide (Vp-16) is a topoisomerase II inhibitor antitumor agent which is widely used in the treatment of several hematologic malignancies. Hydroxyurea is a nonalkylated antitumor drug, which can inhibit DNA synthesis. 2018 Chinese guideline recommended Hu as the first line cytoreductive agent when WBC-4 × 10^9/L during induction [7]. Single agent Hu is difficult to control the rapid multiplication of APL cells in high-risk patients according to our previous clinical experience. NCCN and ELN guidelines recommended anthracyclines or GO due to stronger cytoreductive effect. Lumbar puncture and IT chemotherapy is elective both in ELN guidelines and Chinese guidelines, however we usually do 2–4 times Lumbar puncture and IT chemotherapy in high-risk APL to prevent central nervous system leukemia (CNSL).

The successful experience of these two patients demonstrated that: 1. Cytotoxic drug oral Vp-16 replace anthracyclines as cytoreductive agent at the initial stage of induction therapy for high-risk APL:2. Oral Vp-16 is convenient and it overcomes the limitation of intravenous chemotherapy drugs in some special circumstances; 3. High-risk APL patients should receive oral Vp-16 as early as possible to reduce tumor load in order to secure safety of induction therapy. 4. Oral regimen could avoid Peripherally Inserted Central Catheter, so it could avoid catheter venous thrombosis in the coagulopathy during the early stage. In conclusion, oral Vp-16 cytoreductive regimen combined with ATRA and RIF dual induction therapy is expected as a new mode of high-risk APL treating in outpatient clinics or emergency room, which is worth to explore in the future.

CRediT authorship contribution statement

Sheng-ye Lu: Writing – original draft, Writing – review & editing. Wen-jing Li: Project administration. Rui Lou: Project administration. Rui Ma: Project administration. Ji-hong Zhu: Project administration. Hao Jiang: Investigation, Project administration.

Declaration of Competing Interest

We declare no competing interests.

Acknowledgments

This study was supported by the National Key R&D Program of China (2016YFE0202800).

Reference

[1] H. Dohner, E. Estey, D. Grimwade, S. Amadori, F.R. Appelbaum, T. Buchner, H. Dombret, B.L. Ebert, P. Fenaux, R.A. Larson, et al., Diagnosis and management of acute myeloid leukemia in adults: 2017 eln recommendations from an international expert panel, Blood 129 (9) (2017) 424–447.
[2] L. Ades, A. Guerci, E. Raffoux, M. Sanz, P. Chevallier, S. Lapsus, C. Recher, X. Thomas, C. Rayon, S. Castaigne, et al., Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the european apl group experience, Blood 115 (9) (2010) 1690–1696.
[3] A.K. Burnett, N.H. Russell, R.K. Hills, D. Bowen, J. Kell, S. Knapper, Y.G. Morgan, J. Lok, A. Grech, G. Jones, et al., Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (aml17): results of a randomised, controlled, phase 3 trial, Lancet Oncol. 16 (13) (2015) 1295–1305.
[4] F. Lo-Coco, G. Avvisati, M. Vignetti, C. Thiede, S.M. Orlando, S. Iacobelli, F. Ferrara, P. Fini, L. Cicconi, E. Di Bona, et al., Retinoic acid and arsenic trioxide for acute promyelocytic leukaemia, N. Engl. J. Med. 369 (2) (2013) 111–121.
[5] M.A. Sanz, P. Fenaux, M.S. Tallman, E.H. Estey, B. Lowenberg, T. Naoe, E. Lengfelder, H. Dohner, A.K. Burnett, S.J. Chen, et al., Management of acute promyelocytic leukaemia: updated recommendations from an expert panel of the european leukaemianet, Blood 133 (15) (2019) 1630–1643.
[6] M.S. Tallman, E.S. Wang, J.K. Altman, F.R. Appelbaum, V.R. Bhatt, D. Bixby, S. E. Coutre, M. De Lima, A.T. Fathi, M. Fiorella, et al., Acute myeloid leukemia, version 3.2019, nccn clinical practice guidelines in oncology, J. Natl. Comprehen. Canc. Netw.: JNCCN. 17 (6) (2019) 721–749.
[7] H.H. Zhu, D.P. Wu, J. Jin, J.Y. Li, J. Ma, J.X. Wang, S.J. Chen, X.J. Huang, Long-term survival of acute promyelocytic leukaemia patients treated with arsenic and retinoic acid, Br. J. Haematol. 174 (5) (2016) 820–822.
[8] M.A. Sanz, P. Montesinos, C. Rayon, A. Holowiecka, J. de la Serna, G. Milone, E. de Lisa, S. Brunet, V. Rubio, J.M. Ribera, et al., Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome, Blood 115 (25) (2010) 5137–5146.

[9] M.A. Kutny, T.A. Alonzo, R.B. Gerbing, Y.C. Wang, S.C. Raimondi, B.A. Hirsch, C. H. Fu, S. Mesfinchi, A.S. Gamis, J.H. Feusner, et al., Arsenic trioxide consolidation allows anthracycline dose reduction for pediatric patients with acute promyelocytic leukemia: report from the children’s oncology group phase iii historically controlled trial aaml0631, J. Clin. Oncol. 35 (26) (2017) 3021–3029.

[10] H.X. Zhu, J. Hu, F. Lo-Coco, J. Jin, The simpler, the better: oral arsenic for acute promyelocytic leukemia, Blood 134 (7) (2019) 597–605.

[11] H.H. Zhu, D.P. Wu, J. Jin, J.Y. Li, J. Ma, J.X. Wang, H. Jiang, S.J. Chen, X.J. Huang, Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial, J. Clin. Oncol. 31 (33) (2013) 4215–4221.

[12] M. Gavillet, J. Carr Klappert, D. Sperini, S. Blum, Acute leukemia in the time of covid-19, Leuk. Res. 92 (2020), 106353.

[13] H. Gill, C.R. Kumana, R. Yim, Y.Y. Hwang, T.S.Y. Chan, S.F. Yip, H.K.K. Lee, V. Mak, J.S.M. Lau, C.C. Chan, et al., Oral arsenic trioxide incorporation into frontline treatment with all-trans retinoic acid and chemotherapy in newly diagnosed acute promyelocytic leukemia: a 5-year prospective study, Canc. 125 (17) (2019) 3001–3012.

[14] H.H. Zhu, D.P. Wu, X. Du, X. Zhang, L. Liu, J. Ma, Z.H. Shao, H.Y. Ren, J.D. Hu, K. L. Xu, et al., Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukemia: a non-inferiority, randomised phase 3 trial, Lancet. Oncol. 19 (7) (2018) 871–879.

[15] M. Breccia, F. Lo Coco, Thrombo-hemorrhagic deaths in acute promyelocytic leukemia, Thromb. Res. 133 (Suppl 2) (2014) S112–S116.